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1. INTRODUCTION
In1998,Bikker,Trumpp-Kallmeyer,andHumbletpublisheda
Perspectiveinthisjournalentitled“G-ProteinCoupledReceptors:
Models,MutagenesisandDrugDesign”andreviewedthestateof
the art at that time.
1 No high resolution structure of a G protein-
coupledreceptor(GPCR)hadbeensolved,andresearcherswere
working with models generated with only the structure of
bacteriorhodopsin,
2 which had been published 8 years earlier
and solved using high resolution electron cryomicroscopy
and the low resolution electron density footprint of bovine
rhodopsin.
3 These models, despite greatly improving under-
standing of GPCR structure and function, posed as many
questions as they answered and were not able to clearly rationa-
lize how ligands bound to their target receptor. The authors
stated “The principal limitation of the current generation of
models when used for rational drug design is that the resolution
of the binding cavity is too low to predict speciﬁc ligand receptor
interactions. Attempts to dock ligands into various GPCR
models are further complicated by diﬃculty in identifying
unique, sensible modes of binding, especially when dealing with
molecules of the size of the neurotransmitter ligands.” How
things have changed.
Today, there are six GPCRs for which medium to high
resolution crystal structures have been solved, in most cases with
multiple small molecules ligands. The six receptors are rhodopsin,
the β1 and β2 adrenergic receptors, adenosine A2A receptor,
chemokineCXCR4 receptor, and dopamineD3 receptor (Table1
and references therein). In addition, rhodopsin, the β1 and β2
adrenergic receptors (ARs), and the adenosine A2A receptor have
been solved with both antagonists and agonists bound (Table 1).
Much current research is now engaged in using this new body of
structural information for hit identiﬁcation and drug design
purposes, and we will review the state of the art of both structures
andtheimpacttheyarenowhavingonstructurebaseddrugdesign
(SBDD) for GPCR targets in this article.
While this impressive progress with the structural biology of
GPCRs has been coming to fruition, GPCR drug discovery has
continued to be a major area of pharmaceutical research. Sixty-
three new GPCR drugs have been launched in the past decade,
approximately 24% of all drugs reaching the market during this
period (Table 2). Figure 1 illustrates the 10 ﬁrst in class small
GPCR molecule drugs (new chemical entities, NCEs) from the
past decade (2000 2009). An examination of these molecules
and their targets and a consideration of their druglike properties
highlight a number of issues associated with recent GPCR drug
discovery.First, themoleculesaregenerally attheupper limitsof
Lipinski’srulesintermsofmolecularweightand/orlipophilicity,
suggesting that they would have been “high risk” in terms of
theirADMETpropertiesduringdevelopment.
4Indeed,thereisa
growing body of evidence that molecules with high molecular
weight and in particular high lipophilicity have increased risk of
both toxicity and cross-reactivity giving a high failure rate in the
clinic.
5,6 Second, three of the compounds fall into a “lipophilic
amine” category that is often associated with promiscuous
binders in the GPCR ﬁeld. This suggests that the discoverers
of these drugs would have spent much of their eﬀorts optimizing
receptor activity while tuning oﬀ target activities, including
related receptors, cytochrome P450 enzymes, and ion channels
such as the hERG channel. Third, we can see from Figure 1 that
usually only one new GPCR target has been drugged per year
by an NCE and a consideration of these targets tells us that
thesedrugsaretheculminationofverymanyyearsofresearchon
these receptors by Pharma. During the same decade four
biotherapeutics (NBEs) directed at GPCRs have also been
launched, suggesting that a signiﬁcant number of newer but
clinically validated GPCR targets are currently intractable to
smallmoleculedrugdiscovery.Overall,itiscertainlynotthecase
that modern GPCR targets could be considered “low hanging
fruit”,andtheinventorsofthesedrugsaretobecongratulatedfor
overcoming the considerable challenges of these ﬁrst in class
targets.
2. GPCR PHARMACOLOGY
2.1. Classes of GPCRs. There are 390 GPCRs in the human
genome (excluding olfactory receptors).
7 These fall into three
major classes that, although not related by homology, share the
same overall structural topology of an extracellular N-terminus,
seven-transmembrane spanning domain (TMD), and an intra-
cellularC-terminus.Thelargestsubfamilyistherhodopsinfamily
(also known as family A or class 1). This is the largest and most
diverse subfamily with respect to ligand types. Rhodopsin family
members can be activated by small molecules including amines,
purines, fatty acids, and prostaglandins, as well as peptides to
large glycoproteins. Approximately 25% of marketed small
molecule drugs act through this subfamily of GPCRs.
8 The
secretin and adhesion families (also known as family B or class II)
have related transmembrane domainsbut differ in their N-termini.
The secretin family is activated by large peptides including
glucagon-like peptide (GLP 1), glucagon, and vasoactive intest-
inal peptide. The secretin family is rich in targets that have been
clinically validated through the use of peptides (derivedfromthe
naturalligands)suchasByetta
9(exenatide,GLP1)orMiacalcin
10
(calcitonin). However, to date, this family has proved largely
intractable to small molecule drug discovery, with one exception
being the corticotrophin receptor 1 (CRF 1).
11,12 The adhesion
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family
13 has a seven-transmembrane domain linked to a very long
and highly glycosylated N-termini. The majority of the adhesion
family consists of orphan receptors, and few attempts have been
made to drug this class. The final major subclass is the glutamate
family(familyC,classIII),whichcontainsreceptorsfortheamino
acids glutamate and γ-aminobutyric acid (GABA) as well as the
calciumsensingreceptorandanumberoftastereceptors.
14These
receptorsalsocontainalongN-terminusthatformsanaminoacid
binding domain distinct from the TMD. Drugs acting at this class
of receptors either bind in the amino acid binding domain (e.g.,
Lioresal, baclofen
15) or are allosteric modulators that bind within
the TMD (e.g., Sensipar, cinacalcet
16).
Figure 2 shows cartoon views of the three receptor subclasses
to illustrate the positions of the natural ligand (orthosteric)
bindingsites. InfamilyAthisisinthetopoftheTMDbundle.In
familyBitspansthelargeN-terminal domainand theTMD, and
in family C it exists in the so-called venus ﬂy trap N-terminal
domain. In families A and B the ligand directly activates
the receptor by at least partly binding within the TMD site,
while in family C it is believed that binding of the agonist to the
Table 1. List of Published GPCR Crystal Structures
receptor resolution (Å) PDB code date ref
Rhodopsin: bovine rod outer segment 2.8 1F88 06/00 52
Rhodopsin: bovine rod outer segment 2.6 1L9H 03/02 175
Rhodopsin: bovine rod outer segment 2.65 1GZM 05/02 176
Rhodopsin: bovine rod outer segment 2.2 1U19 07/04 177
Rhodopsin, photoactivated: bovine rod outer segment 3.8 4.15 2I37 08/06 178
Rhodopsin: recombinant bovine rhodopsin mutant, N2C/D282C 3.4 2J4Y 09/06 179
Rhodopsin: squid 3.7 2ZIY 05/07 180
Rhodopsin: squid 2.5 2Z73 08/07 181
Human β2 adrenergic receptor Fab5 complex. Complex with carazalol 3.4/3.7 2R4R 08/07 59
Human β2 adrenergic receptor Fab5 complex. Complex with carazalol 3.4/3.7 2R4S 08/07 59
Human β2 adrenergic receptor: T4 lysozyme replaces ICL3. Complex with carazalol 2.4 2RH1 10/07 60
Opsin: bovine rod outer segment 2.9 3CAP 02/08 78
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with cyanopindolol 2.7 2VT4 05/08 58
Human β2 adrenergic receptor: T4 lysozyme replaces ICL3, E122W stability mutation. Complex with timolol 2.8 3D4S 05/08 182
Opsin in complex with a C-terminal peptide derived from the GR subunit of transducin 3.2 3DQB 07/08 49
Human adenosine A2A receptor: T4 lysozyme replaces ICL3. In complex with antagonist ZM241385 2.6 3EML 09/08 65
Methylated β2 adrenergic receptor: Fab complex 3.4 3KJ6 11/09 183
Human β2 adrenergic receptor: T4 lysozyme replaces ICL3. Complex with the inverse agonist ICI 118,551 2.84 3NY8 07/10 117
Human β2 adrenergic receptor: T4 lysozyme replaces ICL3. Complex with a novel inverse agonist 2.84 3NY9 07/10 117
Human β2 adrenergic receptor: T4 lysozyme replaces ICL3. Complex with alprenolol 3.16 3NYA 07/10 117
CXCR4 chemokine receptor: T4 lysozyme replaces ICL3. Complex with a cyclic peptide antagonist CVX15 2.9 3OE0 08/10 70
CXCR4 chemokine receptor: T4 lysozyme replaces ICL3. Complex with a small molecule antagonist IT1t 3.2 3OE6 08/10 70
CXCR4 chemokine receptor: T4 lysozyme replaces ICL3. Complex with a small molecule antagonist IT1t 3.1 3OE8 08/10 70
CXCR4 chemokine receptor: T4 lysozyme replaces ICL3. Complex with a small molecule antagonist IT1t 3.1 3OE9 08/10 70
CXCR4 chemokine receptor: T4 lysozyme replaces ICL3. Complex with a small molecule antagonist IT1t 2.5 3ODU 08/10 70
Crystal structure of bovine rhodopsin with β-ionone 2.6 3OAX 08/10 184
Dopamine D3 receptor: T4 lysozyme replaces ICL3. Complex with D2/D3-selective antagonist 2.89 3PBL 11/10 36
Human β2 adrenergic receptor in active state stabilized with a nanobody: T4 lysozyme replaces ICL3 3.5 3POG 01/11 80
Human β2 adrenergic receptor with irreversibly bound agonist T4 lysozyme replaces third intracellular loop 3.5 3PDS 01/11 81
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with dobutamine 2.5 2Y00 01/11 82
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with dobutamine 2.65 2Y01 01/11 82
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with carmotorol 2.65 2Y02 01/11 82
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with isoprenaline 2.85 2Y03 01/11 82
Turkey β1 adrenergic receptor: StaR engineered for stability. Complex with salbutamol 3.05 2Y04 01/11 82
Bovine rhodopsin metarhodopsin II 3.00 3PXO 03/11 185
Bovine rhodopsin metarhodopsin II in complex with C-terminal fragment of GR (GRCT2) 2.85 3PQR 03/11 185
Constitutively active rhodopsin mutant with bound GR (GRCT2) 3.00 2X72 03/11 46
Human adenosine A2A receptor: T4 lysozyme replaces ICL3. Complex with the agonist UK-432097 2.7 3QAK 03/11 83
Agonist state human adenosine A2A receptor: StaR engineered for stability. Complex with adenosine 3.0 2YDO 03/11 84
Agonist state human adenosine A2A receptor: StaR engineered for stability. Complex with the agonist NECA 2.6 2YDV 03/11 84
Inverse agonist state human adenosine A2A receptor: StaR engineered for stability. Complex with ZM241385 3.29 3PWH 06/11 66
Inverse agonist state human adenosine A2A receptor: StaR engineered for stability. Complex with XAC 3.3 3REY 06/11 66
Inverse agonist state human adenosine A2A receptor: StaR engineered for stability. Complex with caﬀeine 3.6 3RFM 06/11 664285 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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venus ﬂy trap domain causes a conformational change that
indirectly causes activation via the TMD site. In families B and
C the TMD site is therefore considered allosteric, since the
orthosteric agonists interact principally or entirely with the
N-terminal domains.
2.2. Pharmacology of Drugs Acting at GPCRs. GPCRs are
located in the plasma membrane of all cell types. Here they
mediate the action of a diverse set of extracellular messengers
throughtheirinteractionwithmembraneboundandintracellular
second messenger signaling proteins. Within the membrane,
GPCRs are highly flexible and can exist in a number of conforma-
tional states ranging from the inactive ground state (commonly
known as R) to one or more fully activated states (known as R*)
that interact with and activate signaling proteins including G
proteins. The ratio of R to R* in the absence of ligand varies
from one receptor to another and alters the basal level of
receptor activity. Ligands and drugs that bind to GPCRs alter
the equilibrium between the different conformational states.
17
Untilrecentlylittlehasbeenknownaboutthemolecularnature
of the transitions between conformational states; however, the
recent development in structural biology, in particular struc-
tures of the prototypical GPCR, rhodopsin, is increasing our
understanding of this area.
18,19 Agonists preferentially bind to
andstabilizetheR*stateofthereceptor,resultinginanincrease
in receptor activity. Inverse agonists preferentially bind to the
ground state R and reduce receptor activity. Antagonists act to
blockGPCRactivationbypreventingthebindingofagoniststo
thereceptor.So-calledneutralantagonistsintheorywouldhave
equalaffinityforboth Rand R*;however,inpracticethisisrare
and most drugs referred to as antagonists are in fact inverse
agonists.
17 X-ray structures in complex with agonists and
antagonist ligands are providing information on the early steps
in receptor activation. As discussed above, the binding site of
the endogenous ligand for the receptor is referred to as the
orthosteric binding site. Many drugs also bind to this site or
overlapping sites and are competitive with the natural ligand.
Drugs that bind at distinct sites are called allosteric
modulators.
20
2.3. Allosteric Modulators of G Protein-Coupled Receptors.
Much of historical drug discovery focused on GPCRs has
targeted the orthosteric binding site. However, the advent of
functional screening assays (as opposed to radioligand binding
assays)asascreeningmethodofchoicehasincreasedthenumber
ofallostericligandsbeingidentifiedforGPCRs.Allostericligands
canbindtositesonGPCRsthataretopographicallydistinctfrom
theorthostericsitesuchthatthereceptorisabletoaccommodate
two ligands simultaneously. Allosteric binding sites have been
identified on many GPCRs including adenosine,
21 muscarinic
acetylcholine,
22dopamine,
23chemokine,
24 calcium sensing,
25 and
glutamate
26 receptors.
Themajormechanismofactionofallostericligandsistoeither
enhance or inhibit the binding of the orthosteric agonist, and
ligands are termed positive or negative allosteric modulators
(PAM and NAM), respectively. This modulation in agonist
aﬃnity is reﬂected in a change in the resultant potency (i.e.,
EC50),whichisincreasedordecreased.Allostericmodulators,
unlike orthosteric ligands, have an inherent saturability to
their eﬀect, i.e., a limit on the maximal degree of inhibition or
potentiation of an agonist response. This potential makes
their action more subtle and less prone to target related side
eﬀects.
The advent of functional assays, as opposed to radioligand
binding assays, has had a 2-fold eﬀect. First, it has increased the
numbers of allosteric ligands that are being identiﬁed, but it has
alsoledtotherealizationthatallostericmodulatorscanmodulate
theeﬃciencyofreceptor activationaswellasdirectlyactivatethe
receptor in their own right (in the absence of orthosteric
agonist).
27,28 One notable feature of allosteric modulators is that
their eﬀects depend on the orthosteric ligand in question; this is
referred to as “probe dependence”. For example, the indocarba-
zole staurosporine is a PAM of N-methylscopolamine binding at
the muscarinic M1 receptor but is a NAM of the endogenous
ligandacetylcholine.
29Thisexamplehighlightstheimportanceof
using the endogenous agonist for a receptor when engaging in
allosteric modulator drug discovery.
Of great interest in more recent years has been the structural
basis of allosteric mechanisms. It is thought that by virtue of the
fact that allosteric binding sites are not (generally) utilized by
endogenous ligands, they would be subject to less evolutionary
pressure to be conserved. Thus, they represent an attractive
mechanism for developing receptor-subtype-selective ligands
within GPCR families. Examples of such selective compounds
canbefoundparticularlywithinthefamilyofmuscarinicacetylcho-
line receptors
30 and metabotropic glutamate receptors.
26 For
family C receptors, the orthosteric ligands bind in the large
N-terminal (“Venus ﬂy trap”) domain (Figure 2), whereas most
allostericbindingsiteshavebeenidentiﬁedwithinthetransmembrane
domain region, such as MPEP and CPPHA at the mGlu5
receptor,
31 LY487379 at the mGlu2 receptor,
32 and CGP7930
Table2. GPCRTargetedDrugsLaunchedinthePastDecade
(2000 2009)
a
family A aminergic, opioid, prostanoid
family A peptidergic,
chemokine, other
almotriptan indacaterol abarelix mozavaptan
alosetron lafutidine ambrisentan olmesartan
alvimopan landiolol aprepitant plerixafor
arformoterol levocetirizine atosiban prasugrel
aripiprazole methylnaltrexone bosentan ramelteon
armodaﬁnil nalfuraﬁne conivaptan rimonabant
asenapine paliperidone degarelix sitaxsentan
bepotastine perospirone fosaprepitant taltirelin
betotastine ramatroban ganirelix tolvaptan
bimatoprost rotigotine icatibant
blonanserin rupatadine maraviroc
cevimeline silodosin
darifenacin solifenacin
desloratadine taﬂuprost
dexmedetomidine tapentadol
eletriptan tegaserod
fesoterodine tiotropium
frovatriptan travoprost
Iloperidone treprostinil
imidafenacin ziprasidone
family B family C
exenatide cinacalcet
liraglutide
aNBEs are shown in italics. First in class drugs are shown in bold.4286 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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at the GABAB receptor.
33 Similarly, allosteric binding sites have
been suggested to be present in the transmembrane domain of
family B receptors, such as the CRF-1 receptor.
11
In family A receptors, where the orthosteric binding site is
in the TMD, allosteric binding sites are generally found toward
the extracellular region, formed by the top of the helices and
the extracellular loops,
28 though sites have also been described
on the intracellular face of the receptor, most notably for
chemokine receptors.
34 Unlike in family B and C receptors,
allosteric binding sites on family A receptors tend to be much
closer to the orthosteric binding site and ligands can have two
pharmacophoresthat engage with both orthosteric and allosteric
sites. These have been referred to as “dualsteric”, “multivalent”,
or “bitopic” ligands. This property is thought to underlie the
selectivityproﬁle of some compoundssuch as McN-A-343 at the
muscarinic M2 receptor
35 and R22 (Scheme 4) at the dopamine
D3 receptor,
36 as they engage with allosteric binding sites that
are not conserved between receptor subtypes.
3. COMMON STRUCTURAL FEATURES OF GPCRS
Figure 3 illustrates the key features of GPCRs revealed by
X-ray crystallography from the family A structures to date, using
the β1 adrenergic receptor and dopamine D3 receptor structures
as representative. There are a number of recent excellent reviews
thatdescribethesimilaritiesanddiﬀerencesbetweensomeofthe
recently published structures.
37 40 Throughout this review the
Ballesteros Weinstein residue nomenclature system is used for
amino acid residues.
41 In this numbering method, which is used
for family A, receptors are aligned and the number of the most
conserved residue in each helix is assigned 50. Amino acid
residues are given two numbers (N1.N2) where N1 refers to
theTMnumber(1 7)andN2isthenumberrelativetothemost
conserved (number 50). Numbers decrease toward the N-termi-
nus and increase toward the C-terminus.
3.1. Transmembrane Domain. The TMD consists of seven
R-helices approximately perpendicular to the cell membrane.
Figure 1. First in class GPCR targeted drugs launched in the past decade. The drug, year of launch, protein target, route of administration, MWT, and
cLogP are given in each case. The biological drugs are shown next to the GPCR target and year of launch.4287 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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Figure3showsthecommonnumberingofthehelicesandthat,in
more detail, the R-helices are tilted out of plane. The exact
positions and orientations of the helices differ slightly from one
structure to the next but can be reasonably predicted using
homology modeling methods, especially now that multiple
structures are available. Since GPCRs are R-helical, the back-
bones of these proteins are largely involved in intramolecular
interactions and not available to H-bond to ligands. As such,
generallyonlythesidechainsofbindingsiteresiduesareinvolved
in binding ligands, which to some extent simplifies the modeling
process.
3.2. TMD Ligand Binding Site. The TMD site is a deep
hydrophobic cavity containing key H-bonding residues, specific
to each receptor family, that engage with ligands. In rhodopsin
the ligand retinal is entirely enclosed in its binding site with the
transmembranebundlebetweenTM5andTM6andiscovalently
bound toTM7viaSchiffbaselinkage toLys296(7.43).In theβ2
and β1 ARs and the dopamine D3 receptor the binding site is
more open but the ligands sit in a similar overall position form-
ing interactions principally with TM3, TM5, and TM7. In the
aminergic family A receptors there is always an acidic residue on
TM3 at position 3.32. In the adenosine A2A and CXCR4
receptors the antagonist ligands sit higher in the binding site
and closer to the extracellular surface and the sites are relatively
open. Because of the open nature of the binding sites, the
antagonist ligands do not fill the binding cavity, making it
challenging in silico to correctly predict their binding modes.
Overall it is clear from the structures to date that the position of
the orthosteric ligand binding site is conserved for a broad range
of family A ligands but that the way in which ligands interact in
the site can vary quite considerably. This is dealt with in more
detaillater,andinparticularthedifferencesbetweenbindingsites
areshowninTable3anddescribedinthelegends.Whereligands
are not small molecules, such as in the chemokine family, it is
believed that onlypart of the naturalpeptideligand engageswith
theTMDsiteandthatamoreextendedbindingsitemustexiston
the extracellular face of these receptors.
3.3. ECL2. The extracellular loop 2 (ECL2) extends from the
ends of TM4 and TM5 and sits above the orthosteric binding
pocketoffamilyAGPCRs(Figure3).Inrhodopsinthisregionis
very long, having some β-sheet character within it, and it largely
encloses the binding site. This feature served to confound many
early attempts at homology modeling of GPCRs when only
rhodopsin structures were available, and in general, modeling of
ECL2 is still challenging because this loop is highly variable and
atthesametimeseemstobegenerallyinvolvedinligandbinding.
For example, in β2 and β1 ARs there is a short R-helix within
ECL2 that was not predicted by modeling and Phe193 (β2)o n
the loop is in contact with the bound ligands. The ECL2 often
contains one or more disulfide bridges that serve to rigidify the
loop. It is thought that for a number of receptors that allosteric
binding sites exist at the bridgehead of ECL2 and the top of the
orthosteric site and in some cases bitopic ligands span between
theorthostericsiteandtheECL2 allosteric site.
42,43 Asdiscussed
above, where the natural ligand for a receptor is a peptide, it is
likely that ECL2 is important for ligand binding, and in these
cases the orthosteric site may actually extend from the TMD to
ECL2 on the extracellular surface.
3.4.ToggleSwitch.ImmediatelybelowtheTMDbindingsite
on TM6 is a highly conserved tryptophan residue W6.48 termed
the “toggle switch”
44 (Figure 3). This residue is thought to be
involved in receptor signaling via a change in its rotational state
upon agonist binding that serves to trigger a series of other
changes that propagate to the intracellular surface. Other resi-
dues involved in this conformational change have been termed
“microswitches”.
45 Specifically, the toggle switch forms part of
the so-called CWxP motif at the bottom of the ligand bind-
ing pocket and the rotamer movement is thought to be trans-
mitted through a hydrogen bonding network to the two most
conserved residues in TM1 (Asn55 (1.50)), TM2 (Asp83
(2.50)) (Ballesteros Weinstein nomenclature in parentheses
41),
and another conserved sequence called the NPxxY motif in
TM7. The hydrogen bonding network then extends toward the
G protein peptide with water molecules hydrogen bonding to
both the receptor and G protein. There is good evidence for this
mechanism for rhodopsin, in which the ligand directly interacts
with this tryptophan residue,
46 but the more recent family A
structures have shown no such direct contactwithligands. In the
recent agonist bound structures of β2 and β1 ARs the expected
conformational change has not occurred (discussed later).
However, it remains that this important residue is likely to be
involved in the conformational changes that occur on full
receptor activation, though perhaps in a more modest way than
envisioned in the original rotary toggle switch proposal.
3.5. Ionic Lock. The ionic lock is a salt bridge within the he-
lical bundle on the intracellular face of family A GPCRs.
47 In
rhodopsin, this salt bridge is between Arg135 (3.50) and Glu247
(6.30)andhasbeenhypothesizedtohelpholdthereceptor inan
inactiveconformation.
48Thesetworesiduesformthefirstpartof
the highly conserved “D(or E)RY” region (Figure 3). Despite
this observation, the ionic lock has not been observed in a
number of the published structures that bind antagonists, and
it has been speculated that this may be due to the presence of
antibodyorT4lysozymefusions(introducedtofacilitatecrystal-
lization)thathaveperturbedtheintracellularfaceofthereceptor
structuresorduetothefactthattheligandsarenotinallcasesfull
inverse agonists.
40 The implication is that the ionic lock will
only be “closed” in the full ground state (inverse agonist)
conformation.
3.6. ICL2 and ICL3. Intracellular loop (ICL) 2 extends
between TM3 and TM4 and ICL3 between TM5 and TM6
(Figure 3). These loops are likely to be involved in G protein
binding. The structure of bovine opsin bound to the C-terminus
Figure 2. Overall structures of family A, family B, and family C GPCRs
as a cartoon. The seven helices are labeled in each case, and N-terminal
ECD is shown. The natural ligand is shown in green. In family B this is
the “hot dog in a bun” model where the peptide is shown binding to the
ECD and also to the TMD. In family C the ECD is the “Venus ﬂy trap”;
conformational change upon binding of ligand is thought to cause
receptor signaling.4288 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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of the transducin GRt protein gives direct support for the role of
ICL3 in receptor signaling.
49 In this structure the ionic lock is
broken and there is outward movement of TM5 and TM6.
Comparison of antagonist and agonist structural features is
discussed in more detail later.
4. ANTAGONIST LIGAND RECEPTOR CRYSTAL
STRUCTURES
Theindividualantagoniststructuresarebrieﬂydescribedhere,
focusingon the protein ligand interactions formed in the TMD
binding site and the utility of this information for SBDD
approaches. Table 3 also illustrates the protein ligand interac-
tions for antagonists keeping an identical orientation and is
shown with GRID maps to highlight the diﬀerent shapes and
properties of the sites.
50,51 The table is intended to allow direct
visualcomparisonofthepropertiesofeachofthebindingsitesto
complement the discussion below. Figure 4 shows how each of
the ligands overlays in the same consistent binding mode shown
in Table 3. The ﬁgure indicates how, broadly speaking, all the
ligands bind in the TMD site, but we will see that in ﬁne detail
they make signiﬁcantly diﬀerent interactions to their respective
receptors.
4.1. Rhodopsin. The first X-ray diffraction structure of a
GPCR, bovine rhodopsin, was published in 2000 solved from
bovine retinal disk membranes.
52 This provided a detailed
picture of the ligand binding pocket of a receptor in the full
inverse agonist conformation. The 11-cis retinal ligand makes a
covalent Schiff base linkage to Lys296 (7.43) in TM7. In
addition, residues from TM1, TM2, and TM7 encase the Schiff
base, and the β-ionone ring forms interactions with the side
chainsofPhe208(5.43)andTrp265(6.48),fromTM5andTM6
(Table3entry1andFigure5B).Thisandadditionalstructuresof
the inactive dark-state rhodopsin then provided the basis for
GPCR modeling during the following 8 years.
53 A great deal of
work has been done using bovine rhodopsin as the template for
homology modeling of other GPCRs, and there are a number of
reviews dealing with these developments.
54 56 However, there
areseveralproblemsassociatedwithrhodopsinasastartingpoint
forGPCRmodeling.
56,57First,althoughrhodopsinsharesoverall
structural features with other family A GPCRs, the actual
homology is less than 25% and for other GPCR families such
as thesecretin,adhesion, andmetabotropic receptors,thereisno
detectable sequence homology at all with rhodopsin. Second,
since retinal is covalently bound to the receptor, rhodopsin is
likely to have a very different mechanism of activation to other
receptors with noncovalent ligands. In rhodopsin, signaling is
initially triggered by ligand isomerization via photons of light
and the isomerized ligand becomes the agonist. As such, there
is no requirement for an entrance to the ligand binding site, and
this is actually blocked by the second extracellular loop (ECL2)
of the receptor. Despite these concerns, rhodopsin has success-
fully been used as a starting point for homology modeling,
facilitating SBDD efforts, and some examples are given later in
this article.
4.2. β1 and β2 Adrenergic Receptors. In 2007 and 2008 the
nextmajorbreakthroughsinGPCRstructuralbiologyweremade
when the crystal structures of the turkey β1
58 and human β2
adrenoceptors
59,60 were solved. These GPCR structures, in com-
plex with antagonist ligands cyanopindolol (β1) and carazolol
(β2), were the first with noncovalently bound small molecules in
the binding sites (Table 3, entries 2 and 3). The structure of the
human β2AR was first determined at medium resolution (3.5 Å)
in complex with an antibody fragment
59 and subsequently at
higherresolution(2.4Å)byinsertionoftheenzymeT4lysozyme
(T4L) into ICL3 of the receptor.
60 The fusion proteins were
introduced to aid crystallization of the receptors rather than to
increase thermal stability (see below). This is the first of two
new strategies for the determination of GPCR structures. If the
fusion protein approach is used, it has been coupled with a very
Figure 3. Common structural architecture offamilyAGPCRsrevealed byX-raycrystallography. Thestructures ofβ1AR(green, 2VT4)and D3R(red,
3PBL) are overlaid and used as representative. The key features of the structures are illustrated (see main text for details).4289 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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Table 3. TMD Binding Sites of Published GPCRs Illustrating Protein Ligand Interactions for Antagonists (Left-Hand Side)
a4290 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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aTheindividualligandsareshownkeepinganidenticalview/orientationintherighthandpanel(basedonaproteinstructuredrivenoverlayofthediﬀerentstructures
usingMaestro/Schr€ odinger).GRIDmapstohighlightthediﬀerentshapesandpropertiesofthesitesarealsoshown,withidenticalenergylevelcontours:Csp3(C3)
at1kcal/molinlightgraytodeﬁneshape,thelimitofwhereacarboncanbe.AromaticC Hprobe(C1d) isinyellowat 2.8kcal/molforlipophilic/hydrophobic
hotspots.Carbonylgroup(CdO) isinblueat 4.5kcalforH-bondacceptorhotspots,andamideNH(N1) isinlilacat 6.6kcal/molforH-bonddonorhotspots.
Table 3. Continued4291 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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high potency ligand to aid stability and a highly specialized
crystallization method called lipidic cubic phase (LCP) which
serves to mimic the environment in the cell membrane. The
second strategy, first used in the structure determination of the
turkeyβ1ARtoaresolutionof2.7Å,involvedtheintroductionof
a number of point mutations into the receptor construct that
increased the thermostability of the protein and enabled
crystallization.
58 The thermostabilization approach “locks” the
receptor in a single homogeneous conformation that greatly
facilitates purification and structure determination. The stabi-
lized receptor construct has been termed a “StaR” for stabilized
receptor.
61 By use of the thermostabilization strategy, crystal-
lization can be achieved using more typical vapor diffusion
crystallography methods, albeit in the presence of detergents
required to solubilize the receptor. Consistent with the “con-
formational thermostabilization” hypothesis, the resulting β1AR
antagonist StaR displayed high affinity for antagonists and inverse
agonists but markedly reduced agonist affinity.
58 An important
finding is that these two orthogonal crystallization strategies gave
highlycomparablestructuresolutionsofβ1ARandβ2ARindicating
that (1) none of the point mutations had resulted in perturbations
of the β1AR structure and (2) the fusion protein had not
significantly perturbed the β2AR structure (Table 3, entries 2 and 3).
However, in the case of the β2AR structure and other fusion
protein structures, little information can be gained about the
intracellular receptor surface because of the presence of the
additional protein domain and the fact that the receptor cannot
interact with G proteins. In contrast, the β1AR antagonist StaR
can still be activated by agonists, albeit at much higher concen-
trations than required for the wild-type receptor because of the
reduced agonist affinity of the StaR compared to the wild-type.
58
The ECL2 of both β1AR and β2AR sits above the TMD
binding site and contains an R-helical structure that was not
predicted computationally using rhodopsin as a template; this is
quite diﬀerent from the β-sheet present in rhodopsin in this
region.
62,63 The binding pockets forcyanopindololand carazolol
are very similar in the two receptors, which have a high level of
sequence conservation in the transmembrane domain regions
(Table 3, entries 2 and 3). In fact, in the binding site there are 15
amino acid residues that in β1AR are in contact with cyanopin-
dolol and that are conserved in β2AR.
58,60 In both receptors,
residues fromTM3, TM5, TM6, TM7, andECL2 makecontacts
with the ligands, most notably between the amine group of
cyanopindolol/carazolol and Asp121/113 (3.32) and Asn329/
312 (7.39) and also between Ser211/203 (5.42) (residue num-
bers in β1AR shown ﬁrst) and the indole nitrogen of cyanopin-
dolol or the carbazole of carazolol. There are only very small
diﬀerences between the two structures, such as the rotamer state
of Ser211/203 (5.42). However, despite the high degree of
conservation of the binding site, there are known ligands that
distinguish between the two receptor subtypes pharmacologi-
cally (e.g., CGP20712A). Careful inspection of the binding sites
reveals that although only two amino acid residues within 8 Å of
the β1AR binding site diﬀer in β2AR (Val172 (4.56) and Phe325
(7.35) are Thr164 (4.56) and Tyr308 (7.35), respectively, in
β2AR), these changes do result in some subtle diﬀerences in the
shape andpolarityof thebinding pocket thatmay account for, or
might now be used in, the design of selective ligands, and this is
discussed later. In β2AR, Tyr308 (7.35) has been implicated by
site directed mutagenesis (SDM) studies as playing a role in the
selectivity of agonists because of its ability to form a hydrogen
bond with Asn293 (6.55).
64 As in the case of closely related
enzyme targets, it seems likely that receptor subtype selectivity
could be achieved by SBDD approaches by the exploitation of
minor diﬀerences either in the primary binding pocket or in the
extended region (which includes nonconserved residues) in the
ECL2 that contribute to the binding site(s).
4.3. Dopamine D3 Receptor.Very recently the dopamine D3
receptor structure has been solved at a resolution of 3.15 Å in
complexwiththehighaffinityantagonisteticloprideusingtheT4
lysosyme fusion protein strategy.
36 As expected, the overall
topology is similar to that in the β1AR and β2AR structures
and includes an R helix in ICL2 which was also observed for
β1AR.
58 However, unlike in β1AR and β2AR, the ECL2 was
found to be disordered having no apparent secondary structure.
This is surprising, since the portion of ECL2 that contributes to
ligandbindinginthedopamineD3receptorsiteisorientatedina
similar position relative to the bound ligand compared with the
β1 and β2 ARs. Other notable differences from β2AR include an
outward tilting of TM6 (by 3 Å) and TM7 (by 2 Å) and an
inward tilting of approximately 3.5 Å by TM3 and TM5 at the
extracellular face. Significantly, the “ionic lock” between Arg128
(3.50) and Glu324 (6.30) is formed in this structure,
36 while it is
broken in both of the adrenergic receptor structures (Figure 3).
This would suggest that the ligand has induced a full inverse
agonist conformation in this structure and/or that the T4 lyso-
zyme fusion has had less impact on the structure than in other
receptors. Within the ligand binding pocket it is perhaps of no
surprise that there are many similarities with both the β1AR
and β2AR structures, given the chemical similarity between the
endogenous agonists. Ten of the inward facing residues from
a total of 18 amino acids in the primary binding site are
conserved. As would be predicted from sequence homology to
the β-adrenergic receptors, the tertiary amine of the ligand forms a
saltbridgewithAsp110(3.32).Thearomaticringofeticlopridesits
in a hydrophobic pocket formed by Phe345 (6.51), Phe346
Figure 4. Superposition of ligands from seven diﬀerent GPCR X-ray
structures,basedonCRalignmentoftheGPCRproteinstructures:dark
green = β1AR antagonist; light green = β2AR antagonist; cyan = A2AR
antagonist;lilac=D3Rantagonist;yellow=CXCR4antagonist;brown=
rhodopsin (inactive); gray = A2AR agonist.4292 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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(6.52), Val189 (5.39), Ser192 (5.42), Ser193 (5.43), Val111
(3.33), and Ile183 in ECL2 (Table 3, entry 4). The pyrrolidine
ringsitsinalargelyaromaticregioncomprisingofTyr365(7.35),
Phe106 (3.32), Val86 (2.61), and Tyr373 (7.43). Interestingly
theligandformstwointramolecularhydrogenbondsholdingthe
aromatic ring largely in plane with the amide side chain. Overall,
as can be seen from Table 3, entry 4, the ligand sits in a very
similar position to ligands in β1AR and β2AR.
4.4. Adenosine A2A Receptor. The structure of the A2A
receptorwasfirstsolvedin2008usingtheT4Lfusiontechnology.
65
T4LwasinsertedbetweenLeu209(5.70)andAla221(6.23)inthe
ICL3 of the receptor. The insertion of the T4L was observed to
have somewhat altered the pharmacology of the receptor in that
agonists bound to the receptor with a higher affinity than for wild
type. A2A-T4L was crystallized using the LCP method with the
addition of cholesteryl hemisuccinate (CHS) and in complex with
the inverse agonist ligand ZM241385. There is close agreement in
the packing of the helices between A2A and other receptor
structures; e.g., compared to the adrenergic receptors, the rmsd
is 1.8 2.5 Å, despite a relatively low homology (20 40% in the
TM regions). In our own laboratories a second structure of the
receptor has been solved using the thermostabilization strategy.
66
This receptor, known as A2A-StaR2, includes eight thermostabiliz-
ing mutations spread throughout the receptor that appear to hold
the receptor in an inverse agonist conformation. In contrast to the
A2A-T4L construct the A2A-StaR2 has a lower affinity for agonists
compared to the wild type receptor but a similar or slightly higher
affinityforantagonists.
61Asisthecaseforthe β1AR,themutations
in the A2A-StaR2 appear to have very little direct effect on the
structure compared to the A2A-T4L but rather seem to facilitate
packing between adjacent helices to stabilize the receptor con-
formation.Thetwostructuresareinbroadagreement,butthereare
some significant differences. Most noticeable is a ∼5Åo u t w a r d
movement of TM5 and TM6 observed in the A2A-T4L compared
with A2A-StaR2 most likely due to the presence of the fusion
protein displacing these helices. We propose that these are similar
to the movements observed during receptor activation as seen in
thetransitionofrhodopsinfromthegroundstatetotheactivestate
(opsin) discussed below, and this may account for the observed
“agonist-like” pharmacology of A2A-T4L. The differences in TM6
between the structures are particularly noticeable in the region of
the ionic lock, whichin A2Ais formed between Glu228 (6.30) and
Arg102(3.50).IntheA2A-StaR2theioniclockispresentproviding
furtherevidencethatthisreceptoriscapturedintheinverseagonist
state, while in the A2A-T4L the movement and rotation of TM6
break the ionic lock.
In the A2A receptor the loop regions are held in place by four
disulﬁde linkages. Cys77-Cys166 links the top of TM3 to ECL2
and is highly conserved in family A GPCRs. Cys71-Cys159 and
Cys74-Cys146 link ECL1 and ECL2 and are unique to the A2A
receptor.InadditionthereisanintraloopdisulﬁdebondinECL3
between Cys259 and Cys262. The disulﬁde bonds create a rigid
structure that produces an open entrance to the ligand binding
pocket that may facilitate access of ligands. The inverse agonist
ligand ZM241385 sits in quite a diﬀerent position compared to
retinal and to the aminergic ligands within the TMD ligand
binding pocket (Table 3, entry 5). In fact, ZM241385 sits almost
perpendicular to the membrane plane with its furan ring deep
within the binding pocket, interacting with Asn253 (6.55) and
Glu169 (ECL2), while at the other end of the ligand the phenol
Figure5. TMDbindingsitesofpublishedGPCRsillustratingprotein ligandinteractionsforagonists(cyanligands)comparedwithantagonists(pink
ligands): (A)generalchangesonantagonist toagonisttransitionexempliﬁedusingrhodopsin (red)andopsin (green);(B)rhodopsinagoniststructure
(green) 2X72 vs antagonist structure (red) 1HZX; (C) β2AR agonist structure (green) 3POG vs antagonist structure (red) 2RH1; (D) A2AR agonist
structure (green) 3QAK vs antagonist structure (red) 3EML.4293 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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ring projects toward the extracellular region of the receptor. The
B factor (or temperature factor, a crystallographic measure of
disorder)oftheﬂexiblephenolgroupintheA2A-T4Lstructureis
high (>100 Å
2) compared to the rest of the ligand (∼50),
suggesting that the position of this substituent should be inter-
preted with caution.
67 As well as the furan, the heterocycle of the
ligand also forms a H-bond to the Asn253 (6.55). The Asn253
(6.55) has previously been predicted by SDM experiments to
form a key interaction with a broad range of ligands, and its
mutationabolishesligandbinding.
68ZM241385doesnotbindto
the entirety of the binding pocket and the region proposed to
interact with the ribose of the natural agonist ligand adenosine,
adjacent to the polar residues Thr88 (3.36) and Ser277 (7.42),
and the toggle switch Trp246 (6.48) is unoccupied.
68,69 How-
ever, there is a network of water molecules that interact with the
ligand in this region. The involvement of water networks in
ligand binding is commonly observed in SBDD but creates an
issuefordenovodocking tohomology models,as itisdiﬃcultto
predict the exact position and role of waters within a large and
openbindingcleftintheabsenceofX-raydata.Crystalstructures
are normally required to identify water molecules relevant to
drug design in a SBDD paradigm.
4.5. Chemokine Receptor CXCR4. CXCR4 is one of the
family A chemokine receptor subfamily of which there are 19
members. Chemokines have large peptides as their natural
agonists, and in this case the ligand is stromal-derived factor
(SDF) 1 (CXCL12). The structure of CXCR4 has recently been
obtainedincomplexwithbothcyclicpeptideandsmallmolecule
antagonists.
70 This is the first example of a peptide GPCR to be
solved and so represents a major breakthrough in understanding
the diversity of GPCR structures and for modeling chemokine
and other peptide receptors for drug discovery. The receptor
structure was obtained using a construct that included the T4L
fusion but also contained two thermostabilizing mutations
(L125W (3.41) and T240P (6.36)). The antagonists used for
crystallization were IT1t (an isothiourea) and CVX15 (a 16-
residue cyclic peptide antagonist) (Table 3, entry 6). In all, five
structures have been deposited in the Protein Data Bank (PDB)
that differ in the truncation of the C-terminus, the presence or
absence of the T240P (6.36) mutation, and the ligand (IT1t or
CVX15). However, each structure included the L125W (3.41)
mutationandtheT4Lfusion.TheN-terminal26residuesarenot
visible in the structure and are presumably disordered. Although
the overall fold of the TMD is the same, TM1 is shifted toward
the core helical bundle compared to the aminergic receptors.
This could be interpreted as a feature of peptide receptors in
which ligands bind primarily to the N-terminus of the receptor
but must still be able to engage the TMD to trigger the
conformational changes associated with receptor activation.
Other key differences are (1) a rotation in the extracellular end
of TM2 resulting from a tighter turn around a conserved proline
(2.58), (2) significant differences in the positions of the ends of
TM4,and(3)ashiftintheextracellularendofTM6comparedto
the β-adrenergic and adenosine A2A receptors.
The intracellular C-terminus of CXCR4 is signiﬁcantly diﬀer-
ent from the other published GPCR structures. TM7 is shorter
by one helical turn, ending in the NPxxY motif, and there is no
R-helix in the C-terminal tail, sometimes called helix 8. The
structuredoesnotcontainthefullR-helicalmotifusuallypresent
in this region and does not apparently have a palmitoylation site
whose function is to tether the C-terminus to the plasma
membrane. It is possible that chemokine receptors do not have
the usual helix 8, or perhaps the absence of this feature is an
artifact of the crystallization constructs used in these studies.
Allosteric modulators have in fact been identiﬁed to related
chemokine receptors which bind to an intracellular binding site
that was believed to be in the region of helix 8. For example,
SB265610 behaves as an allosteric inverse agonist of CXCR2.
This compound’s binding is aﬀected by mutations K320A,
Y314A in the C-terminal tail and D84N (2.40) in TM2.
71 A
similar binding site has been identiﬁed for other CXCR2
antagonists
34 and is also thought to exist in CCR4 and CCR5
receptors.
72
The CXCR4 structure gives insight into how non-peptide
antagonist ligands can block the activity of the much larger
peptide agonist CXCL12. Historically, a two-site model of
activation or a message address concept has been suggested
to explain thebindingof largepeptideor hormone ligands.“Site 1”
represented the address or ligand recognition site, and in the
case of opioids and neurokinins this site was proposed to
determine the speciﬁcity of ligand/receptor interactions.
73,74 In
peptide receptors this site was postulated to be located in the
extracellular regions of the protein including the N-terminus
and/or the extracellular loops such as ECL2. Indeed, NMR
structures of the N-terminus of CXCR4 in complex with SDF 1
havebeen determined,whichhelp tosupport these ideas.
75Such
an extracellular binding site would involve multivalent binding
interactions between the receptor and peptide ligand akin to a
protein protein interaction and that would most likely be
diﬃcult to inhibit with small molecule antagonists. However,
“site 2” or the message region is the binding site that triggers
receptor activation and signaling and is believed to involve the
N-terminus of the peptide ligand making contact with the TMD
binding site, analogous to the orthosteric binding site of aminer-
gicreceptors.
76TheCXCR4structuregivesustheﬁrstviewofan
example of this “site 2” or “message” binding site for peptide
receptors.AcidicresiduesAsp187(inECL2),Glu288(7.39),and
Asp97 (2.63), which are important for the binding of the
N-terminus of CXCL12, also interact with the small molecule
antagonist IT1t as well as the peptide CVX15 (Table 3, entry 6).
IT1t also forms hydrophobic contacts with Trp102 (ECL1),
Val112(3.28),Tyr116(3.32),Cys186(ECL2),Arg183(ECL2),
and Ile185 (ECL2).Overall,thesmallmoleculesits higher inthe
TMD site than other small molecule antagonist ligands in the
crystal structures to date, and we might expect that agonist
signaling will involve interactions with residues deeper in the
binding site and closer to the toggle switch.
5. AGONIST LIGAND RECEPTOR CRYSTAL
STRUCTURES
Until very recently, a view of the agonist GPCR conformation
and how it varied from the antagonist form was only available
from progress in the structural biology of the rhodopsin/opsin
system.
77 As described above, before 2011 all of the diﬀusible
ligand costructures of family A GPCRs were with antagonist
ligands. However, new breakthroughs with structures that bind
agonist ligands now start to give a picture of how agonist
signaling may occur. The structural features associated with the
antagonist to agonist transition will be discussed in this section
and are also shown in Figure 5.
5.1. Opsin. Evidence of the structural basis of GPCR activa-
tion has come from solutions of the structure of the activated
apoprotein form of rhodopsin, called opsin, in complex with a4294 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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peptidederivedfromtheC-terminaltailofthereceptor’scognate
G protein, transducin.
49,78 These structures show significant
movements of TM5 and TM6 when compared to the ground
state of rhodopsin, with the cytoplasmic end of TM6 moving
outward by 6 7 Å. Figure 5A indicates the movements of the
seven helices; these conformational changes in the transmem-
brane domain region are thought to underlie the process of
receptoractivation.Notably,theionic lock, asaltbridge between
Arg135 (3.50) and Glu247 (6.30), is also broken in these struc-
tures; this is another element that is thought to contribute to the
activationprocess.
79Changesinotherso-called“microswitches”are
also observed.
45 More recent insights into the stages of receptor
activationhavecomefromanagonist-boundstructureofrhodopsin
containing a constitutively active mutation E113Q (3.28)
46
(Figure 5B). The agonist, all-trans-retinal, does not appear to be
covalently bound to the receptor. There is also a change in the
rotameric stateofthetoggleswitchTrp265(6.48) thatislocatedat
thebaseofthebindingsiteintheCWxPmotif.Thisconformational
change is thought to be caused by a rearrangement of the water-
mediated hydrogen bonding network involved in agonist binding
a n di st r a n s m i t t e dt h r o u g ht ot h et w om o s tc o n s e r v e dr e s i d u e si n
TM1 (Asn55 (1.50)) and TM2 (Asp83 (2.50)) and the NPxxY
motif in TM7. The network of hydrogen bonds continues into the
site of receptor G protein peptide interaction; the rearrangement
of interactions from the agonist-binding site to the G-protein-
binding site likely represents the mechanism by which the receptor
becomes active and able to couple to G proteins. In addition to
advancing our knowledge of receptor activation these new struc-
tureswillbeusefulfordevelopingmodelsofagonistbindingforuse
in virtual screening and drug discovery.
5.2. β1 and β2 Adrenergic Receptors. A wider level of
understanding of the structural basis of receptor activation
beyond rhodopsin has come from various recent studies examin-
ing agonist-bound structures of the β1 and β2 adrenergic
receptors. Initial evidence regarding the differences between
agonist and antagonist binding came from the structure of
the cyanopindolol-bound β1AR. Docking of adrenaline into the
cyanopindololbindingpocketsuggestedthatbecauseofthesmaller
size of the agonist compared to the antagonist, the distance
between the serine residues on TM5 and the catechol hydroxyl
groups of the agonist would be too great to form the expected
hydrogen bonds. Agonist binding and receptor activation
would therefore necessitate a contraction of the binding pocket
by 2 3 Å, likely involving movement of TM5.
58 However, these
proposed changes at the level of the ligand-binding site did not
explain how agonist binding would result in the 5 6 Å movement
at the base of TM6 which was observed in the rhodopsin/opsin
system.
77
More recent studies have yielded greater insights into mecha-
nisms of agonist binding and the initial conformational changes
involvedinreceptoractivation.Theseincludethedescriptionofa
crystal structure of the β2AR-T4L fusion in complex with a high
aﬃnityagonistBI167107andananobodythatactsasasurrogate
forthecognateGprotein.
80Simultaneously,acrystalstructureof
an agonist (FAUC50) irreversibly bound to the β2AR has been
described
81 as well as multiple cocrystal structures of partial and
full agonists in complex with the β1AR.
82 Figure 6 illustrates the
diﬀerences between the β1AR agonist and antagonist bound
structures in the binding site, while Figures 5C depicts the
corresponding β2AR structures.
Although the data sets for β1AR have been determined using
a receptor construct stabilized by mutagenesis in the antagonist
conformation, the receptor can still bind and be activated by
agonists,
58 albeit at higher concentrations than required for the
wild-type receptor. High resolution costructures (all at 3 Å or
less) have been determined for both partial agonists (salbutamol
anddobutamine)andfullagonists(carmeterolandisoprenaline).
82
The overall topology of the β1AR is very similar when complexed
withantagonists,partialagonists,andfullagonists,thoughthereare
subtle diﬀerences in the binding site. As might be expected from
mutagenesis data, the amine moieties of all the agonist ligands
(plus the β-hydroxyl for all agonists except dobutamine) form
interactions with Asp121 (3.32) and Asn329 (7.39). All of the
agonists form a hydrogen bond with Ser211 (5.42); additionally,
the full agonists isoprenaline and carmeterol (but not the
partial agonists) form a second hydrogen bond with Ser215
(5.46) in conjunction with a change in the rotamer state of
Ser212 (5.43) to form a hydrogen bond with Asn310 (6.55)
(Figure 6).
82
Notably,thenumberofpolarinteractionsformedbytheserine
residues on TM5 appears to represent a marker of partial versus
fullagonism.Theformationofthesepolarinteractionscausesthe
binding pocket to contract by approximately 1 Å in comparison
with the cyanopindolol costructure (Figure 6). However, it is
clearthattheseconformationalchangesdonotresultinthelarger
scalemovementsofTM5andTM6thatmightbeexpectedbased
on the opsin structure. It is likely that, despite binding agonists,
because the receptor construct used was one stabilized in an
inactive conformation, these changes simply represent the ﬁrst
stage of movements that result in full receptor activation. Similar
resultshavebeenshownfortheβ2ARincomplexwithBI167107
andananobodythatmimicstheactionsoftheGprotein,shifting
the receptor into a high-agonist aﬃnity state (Figure 5C). This
breakthrough has enabled the agonist-bound structure to be
solved at a resolution of 3.5 Å.
80 Unlike the β1AR study (where
low aﬃnity agonists were proﬁled), the β2AR-T4L system
requires a high aﬃnity ligand, preferably with a slow oﬀ-rate, to
engender stability to the complex.
80 It is this property that
enabled the costructure of an irreversibly binding agonist,
FAUC50, also to be determined.
81
Comparison of the nanobody-bound β2AR structure with the
previously solved carazolol-β2AR costructure (lacking the
nanobody) shows that there is a clear outward movement at
the base of TM6 caused by its rotation, coupled with an inward
movement of TM5 and TM7 and an upward shift along the axis
of TM3 in the β2AR structure in the presence of the nanobody
and BI167107; the 11 Å movement at the base of TM6 is
Figure 6. Comparison of antagonist and agonist ligands bound to the
stabilized β1AR receptor complex, indicating new polar interactions
formeduponagonistbinding.Antagonistligandinmagenta(2VT4)and
agonist in gray (3YO3).4295 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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comparabletothatseenfortheactiveversustheinactivestatesof
rhodopsin.
77 As well as the obvious conformational changes at
the cytoplasmic face of the receptor, the changes in the ligand-
binding site are larger than those observed in the β1AR
80,82
(Figure 5C vs Figure 6). The binding mode of the agonist ligand
isverysimilartothatoftheantagonistcarazololwithinteractions
with both Asp113 (3.32) and Asn312 (7.39) (Figure 5C). In
addition, polar interactions with serine residues on TM5 Ser203
(5.42) and Ser207 (5.46) are enabled by a ∼2 Å inward move-
ment of TM5 and by smaller movements of TM6 and TM7.
Despite the conformational changes throughout the receptor
consistent with receptor activation, there was no change in the
rotamerstateoftheTrp286(6.48),whichhasbeenproposedasa
“toggle switch” for receptor activation.
5.3. Adenosine A2A Receptor.During the preparation of this
manuscriptthestructureoftheagonist UK-432097boundtothe
adenosine A2A-T4L construct was published.
83 This break-
through allows direct comparison of the structure with the
antagonist ligand ZM241385 in the same receptor construct,
previouslypublishedbythesamegroup.
65Theinduced fitofthis
large ligand appears to have trapped the agonist conformation of
thereceptor,affectingtheshapeandcharacterofthebindingsite.
Compared with the antagonist-bound structure, there is a small
outward tilt and rotation of the cytoplasmic half of TM6, a
movement of TM5, and an upward shift of TM3, overall
resembling the changes seen between rhodopsin and opsin.
The changes within the binding site are more profound than
seenfortheβadrenergicreceptorbutaresupportedbyextensive
SDM evidence that supportsthe ligand position and interactions
made.
68,69 Figure 5D illustrates the binding mode of UK-432097
compared withZM241385 intheTMDsite. Thekey H-bonding
with Asn253 (6.55) is maintained with the purine ring, and the
ribose moiety pushes deeply into the bottom of the pocket
forming new polar interactions, absent in the antagonist-bound
structures,withThr88(3.36), His278(7.43),andSer277(7.42).
The upward movement of TM3 causes Ile92 (3.40) to move up
and create a hydrophobic cavity that is in turn occupied by Pro189
(5.50) on TM5. Very recently a structure of the A2A receptor
thermostabilized in the agonist conformation has also been
published.
84 Thermostabilization has enabled costructures to be
obtained with the relatively low affinity agonists adenosine and
N-ethylcarboxyadenosine (NECA). This structure shows similar
changes to the binding site and helical movements observed in the
UK-432097 structure. Overall the changes observed within the
binding site are a very useful addition to the tool box of the
computational chemist, providing a further template for the homol-
ogymodeling of the agonist conformation of family AGPCRs from
a subfamily different from that of the adrenergic receptors.
6. EXTRACELLULAR DOMAINS
Family B and family C GPCRs have large extracellular
domains (ECD) that are involved in ligand binding (Figure 2).
Progress has been made in SBDD with agents that target these
binding sites, and examples are given in this section.
6.1. Family B Extracellular Domain Structures. Family B
contains the secretin group of 15 receptors that consist of the
TMD and an N-terminal ECD that binds peptide hormone
ligands including glucagon-like peptide, calcitonin,and parathyr-
oid hormone.
7 The proposed mechanism of receptor activation
requires binding of the peptide hormone in an R-helical con-
formation to both the extracellular domain and also into the
“message” region within the TMD (Figure 2).
85 A number of
these receptors represent attractive drug targets, and in some
cases modified versions of the native agonist peptides have been
used in the clinic. For example, a stabilized version of glucagon-
like peptide, liraglutide, was recently approved for the treatment
of type II diabetes (Table 2).
86 To date, it has been very difficult
to discover non-peptide modulators that bind to the TMD
allosteric binding site for this class of receptors by using
conventionaldrugdiscoveryapproachessuchashighthroughput
screening (HTS). However, structures of the extracellular do-
mainsofseveralmembersofthefamily,insomecasesincomplex
with peptide ligands, have been solved by X-ray crystallog-
raphy
87,88orbyNMRspectroscopy.
89Theselargepeptideligands
tend to contain amphipathic helices binding into a central hydro-
phobic groove formed by a three-layer R β β R fold ECD,
resemblinga“hotdoginabun”(Figure2).
88Sincethisorthosteric
site has a large protein protein interface, it is difficult to block or
mimic the peptide agonist with a small molecule inhibitor. This
may explain the generally intractable nature of this class of
receptors with regard to small molecule drug discovery.
One exception, however, is the progress made against the
calcitonin gene related peptide (CGRP) receptor. This receptor
isunusualinthatitconsistsofamultimericcomplexoftheseven-
transmembrane protein calcitonin-receptor-like receptor (CLR)
and also a single transmembrane protein, receptor activity
modifying protein (RAMP) 1.
90 CGRP acts as a potent
Figure 7. (A) ECD of the CGRP receptor crystal structure (3N7S). Shown is the N-terminal domain CLR (green) in complex with RAMP 1 (red).
(B) Olcegepant (blue) binds at the interface of CLR and RAMP 1.4296 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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vasodilator and has been implicated in migraine, and several
smallmoleculepeptidomimeticCGRPreceptorantagonistshave
enteredclinical trials for this indication.
91 A recent breakthrough
has beenthe publicationofX-raystructuresofthe CLR/RAMP1
heterodimer ECD in complex with the clinical antagonists
olcegepant and telcagepant (Figure 7).
92 RAMP1 is a three-helix
bundle that interacts with the N-terminus of CLR through
hydrophobic and electrostatic interactions (Figure 7A). The
antagonistligands bindto a cleft formed at theinterface between
the CLR and RAMP1 (Figure 7B). The structures show that
there are multiple ligand protein interactions being formed in
this pocket and the ligands need to span the distance between
a hydrogen bond donor acceptor site on CLR and a hydro-
phobic pocket on RAMP1 for high aﬃnity. Olcegepant forms
hydrogen bonds to the backbone of Thr122 and side chain of
Asp94 on CLR, the side chain of RAMP1 Asp71, and a water-
mediated hydrogen bond at the CLR-RAMP1 interface invol-
ving` CLR Arg38 and RAMP1 Arg67. Antagonism via this
mode therefore seems to require a high molecular weight
compound; both olcegepant and telcagepant are greater than
500 Da in size.
6.2. Family C Extracellular Domain Structures. The meta-
botropic glutamate (mGlu) receptors are examples of family C
G-protein-coupled receptors, most notable for the presence of a
large bilobed N-terminal domain that forms the orthosteric site
for glutamate binding. This N-terminal domain is thought to
close upon agonist binding (hence the term “Venus fly trap”
domain,Figure2),transmittingreceptoractivationviaacysteine-
rich region to the more familiar seven-transmembrane spanning
domain. There are eight mGlu receptor subtypes, which sub-
classify into three main groups (I III) based on their pharma-
cology and G-protein-coupling profile. Types 2 and 3 meta-
botropic glutamate receptors are members of the group II mGlu
receptorsandareexpressedpresynapticallyintheCNSwherethey
regulate transmission of the excitatory neurotransmitter gluta-
mate. As schizophrenia is a disease in which there is excessive
glutamate release in the cortex, there has been great interest in
discoveringselectiveagonistsofthemGlu2andmGlu3receptors
that would act via presynaptic autoreceptors toreduce glutamate
levels.
93
Despite the high conservation of residues forming the binding
site,initialworktodiscoversubtype-selectiveagonistsfocusedon
analogues of the endogenous agonist L-glutamate. Most notable
in terms of group II mGlu receptors was the discovery of DCG-
IV, a cyclized analogue of glutamate that displayed high aﬃnity
and selectivity for mGlu2 and mGlu3 over the other mGlu
receptor subtypes.
94,95 This has been followed by bicyclic
compounds such as LY354740,
96 LY379268,
97 and LY404039,
98
whichnotonlydisplayimprovedselectivityformGlu2/3receptors
but had suﬃcientdruglike properties to be considered suitable for
clinical development in anxiety and/or schizophrenia. Indeed,
recent studies have shown that a prodrug of the active compound
LY404039 is eﬀective in a phase IIa trial in schizophrenia, promp-
ting further interest in this approach.
99
It was during the development of these agents that the crystal
structures of the N-terminal ligand binding domains of members
of the mGlu receptor family have been solved, including that of
the mGlu1 subtype
100 and those of the mGlu3 and mGlu7
receptors.
101 These structures have both aided the design of
mGlu receptor ligands and permitted a retrospective analysis of
the selectivity proﬁle of some ligands which may lead to
improved compounds in the future. Five cocrystal structures of
the mGlu3 N-terminal domain were solved, including solutions
with both L-glutamate and the more selective group II agonist
DCG-IV (Figure 8). Interestingly, the hydrogen bonding net-
work between L-glutamate and the binding site of mGlu3 was
almost perfectly replicated in the DCG-IV costructure, with the
exception of hydrogen bonds mediated through two water
molecules to Ser278 and Arg64. Two of the three water
molecules found in the L-glutamate costructure are absent in
the DCG-IV structure because of the presence of the carboxy-
late side chain on the cyclized core of the ligand. Importantly,
this moiety makes van der Waals interactions with the side chain
of Tyr150 which are absent in the L-glutamate structure
(Figure 8).
101 While L-glutamate can be easily accommodated
in the binding sites of both the mGlu1 and mGlu3 receptor, the
binding of DCG-IV is impaired by the presence of Trp110 in
mGlu1 in place of Tyr150 in mGlu3. At ﬁrst site, this change
appears relatively conservative, but the crystal structures reveal
that the indole ring of Trp110 in mGlu1 is almost perpendicular
Figure8. (A)ECDofthemGlu3receptorcrystalstructurecomplexboundtoglutamate(2E4V).(B)DCG-IVcomplexindicatingdiﬀerencesbetween
mGlu1 (yellow) and mGlu3 (red) that give rise to selectivity.4297 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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to the phenol ring of Tyr150 of mGlu3; such an orientation
sterically blocks the binding of DCG-IV (Figure 8).
101 Similar
observationshavebeenmaderegarding thesubtypeselectivityof
the bicyclic agonist LY404040.
102 The binding of DCG-IV to
mGlu7 also appears unfavorable because the van der Waals
interaction with the Tyr150 of mGlu3 is absent in group III
mGlu receptors.
101 These observations almost certainly underlie
the selectivity proﬁle of DCG-IV for the mGlu2 and mGlu3
receptor subtypes. Homology models and the crystal structures
are now being used to interpret data sets for some of the newer
constrainedbicyclic analoguesof DCG-IV.LY379268, LY389795,
LY404039, and LY404040 are all heterocyclic variants of the
prototypical agonist LY354740.
96 98 Structural insights have
yielded very speciﬁc understanding of the pharmacology of these
compounds: LY404040 and LY404039 are diastereomeric sulf-
oxide analogues of the sulﬁde-containing agonist LY389795.
However, LY404040 has approximately 30-fold and 550-fold
higher aﬃnity at mGlu2 and mGlu3, respectively, than its diaster-
eoisomer LY404039. This is due to the fact that the sulfoxide
oxygenofLY404040isorientedwithinhydrogenbondingdistance
of the phenol of Tyr326, an interaction that is not feasible for the
diastereomer LY404039.
98
7. SBDD AGAINST GPCR TARGETS
It is beyond the scope of this Perspective to review the full
scopeofthemanySBDDprogramsreportedforGPCRtargetsin
recent years. There has been extensive use of homology model-
ing and virtual screening, and a huge body of site directed
mutagenesis data have been generated to support drug discovery
eﬀorts across a wide range of targets.
103 116 However, in the
following section we will brieﬂy highlight some examples to
illustrate strategies that have been employed and in particular
wherethenewGPCRstructuralinformationdescribedabovehas
started to be used directly for SBDD.
7.1. β Adrenergic Receptors. The recent publication of the
crystalstructuresofvariousantagonistandagonistligandsbound
to the β1AR and β2AR has stimulated much interest in the
academic community, leading to a spate of publications. Wacker
et al.
117 have described X-ray cocomplexes of three ligands 1 3
binding to β2AR-T4L (following up from their earlier crystal
structures of carazolol 4 and timolol 5) and then carried out
cross-dockingofallfiveligands(Scheme1).Asexpected,thebest
docking scores were given from self-docking (ligand into its own
structure), but good results were also achieved for other solu-
tions. The ligand binding site was generally found to be quite
rigid with ligands in similar positions relative to each other in
each case. Kolb et al. have used the X-ray complex of β2AR
(2RH1) for virtual screening of one million compounds with
leadlike properties to examine the applicability of the system for
hit discovery using docking protocols.
118 Twenty-five virtual
hits were selected and tested in a radioligand binding assay. Six
hits(Kiof9nMto3.2μM)wereconfirmed(24%hitrate)falling
into two main chemical classes, including 2 which has been
crystallizedbyWackeretal.above(Scheme1)and6(Scheme2).
Similarly, Topiol et al. carried out docking and virtual screen-
ing using β2AR of both an in-house database and external
database.
40,56 Both databases gave good results; 36% and 12%
hit rates for the in-house and commercial libraries, respectively
(Ki of 0.1 nM to 21 μM and Ki of 14 nM to 4.3 μM), compared
with 0.3% hit rate for screening of a set of randomly selected
molecules. As well as rediscovering the well-known hydroxyla-
mine chemotype for β2AR, such as the potent inhibitor 7 in
Scheme 2, new chemical classes of hits were also discovered.
Costanzihasexaminedhowwellhomologymodelsofβ2AR-T4L
based on bovine rhodopsin compare with the crystal structure
solution.
119 A recurring theme in modeling of GPCRs is the
difficultyincorrectlypredictingtheconformationandpositionof
the extracellular loops. The best results were achieved building
ECL2 de novo rather than basing the conformation on bovine
rhodopsinwherethislooppartiallyoccludesthebindingsite.The
binding mode of the crystallographic ligand carazolol could be
successfully recapitulated bydocking into themodel,particularly
when SDM data were taken into account to manually adjust the
model in the binding site. This work also serves as an example to
illustrate that even quite small errors in the positions of residues
within the ligand binding pocket will perturb ligand docking. To
overcome this problem, generation of multiple models and
consideration of SDM and SAR data are often important to
generate useful results. de Graaf and Rognan have used the
β2AR-T4L structure to develop a “customized” model that
binds partial and full agonists.
120 The rotameric states of
Ser212 (5.43) and Ser215 (5.46) within the binding site were
adjusted to facilitate H-bonding of the receptor to the catechol
hydroxyl groups (or equivalent functionality) of agonist ligands.
Scheme 1. Antagonists of β2AR Used in Both Cocrystal Complexes and Comparative Docking Studies4298 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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The modified receptor binding site then performed better than the
X-ray structure in distinguishing partial/full agonists from decoy
ligands in docking runs. The authors suggest that antagonist
structurescanbeusedastemplatesforagonisthomologymodels
and subsequent agonist ligand identification if appropriately
modified, i.e., from knowledge of the effect of SDM on agonists
vs antagonists. These modified models were then representative
of “early activated” conformations for virtual screening. An
example of drug design has been reported by Soriano-Urs  ua
and colleagues in which boron-containing analogues of β2AR
agonists were proposed from docking against the β2 receptor
binding site.
121 One new agonist BR-AEA 8 (Scheme 2) was
shown to be more potent than the corresponding diol agonists
from which they were derived in a functional assay (relaxation of
isolated guinea pig tracheal rings). The analogues were also
shown to be competitively antagonized by β2AR antagonists. In
another recent report, Hattori et al. have studied dockings of a
numberofβ3ARagoniststorationalizeobservedselectivityusing
β2AR (2RH1) as the template for generation of a β3AR
homology model.
122 The potent and selective ligands, such as
9(Scheme 2),included extensionsdesigned toaccess aregionof
the binding site where the receptors were predicted to signifi-
cantly differ at the entrance to the binding pocket.
7.2. Adenosine Receptors. The adenosine receptor family
has been extensively studied over the years in search of both
agonists to treat asthma and antagonists to treat Parkinson’s
disease and cognitive disorders.
67,123 129 Similar to the case for
the β adrenergic receptors, the advent of a published crystal
structure of the adenosine A2A receptor bound to the ligand
ZM241385 has stirred considerable interest in the field. Michino
et al. evaluated the value of GPCR structure prediction by
initiating a community wide, blind prediction assessment of the
ligand receptor X-ray complex of ZM241385 to A2A-T4L.
130
Twenty-nine groups participated, submitting 206 structural
models before the release of the experimental coordinates for
thecrystalstructure.Theclosestmodelhadaligandrmsdof2.8Å
and a binding site rmsd of 3.4 Å. The results indicated that
predictions, particularly of ligand receptor binding mode and
ECL conformations, remain challenging and additional insight
from experimental data (such as SDM) on a receptor may be
required to give good results. Carlsson et al.
131 have used the
adenosineA2A-T4LX-raystructure(3EML)tocarryoutavirtual
screen of 1.4 million compounds and selected 20 for testing. Of
these seven (35%) were found to be hits with affinities in the
range 200 nM to 8.8 μM in a radioligand binding assay, of which
10 (Scheme 3) is an example. All of the hits were shown to be
antagonists in a functional assay and most were selective versus
the closely related adenosine A1 and A3 receptors. Analogues of
the most potent hits were selected and tested, and a number
of additional submicromolar hits were discovered. The binding
modesofthehitswereproposed,andallcompoundsappearedto
form H-bonds with Asn253 (6.55) and Glu169 (ECL2) in a way
related to the X-ray ligand ZM241385. Katritch et al. perfor-
med a virtual screen of adenosine A2A-T4L with 4.3 million
compounds.
67 Twenty-three of 56 experimentally tested mol-
ecules were active (41%), and affinities were in the range 32 nM
to 10 μM, e.g., compound 11 (Scheme 3). All hits were again
shown tobeantagonists,but selectivity was relatively low against
the adenosine A1 subtype in this case. Binding modes for
representativehits weregivenandweregenerallyconsistentwith
thosesuggestedbyCarlsson etal.above.Serendipitously,onehit
molecule was shown to be a very potent adenosine A1 receptor
Scheme 2. Antagonists of β2AR (6 and 7) Identiﬁed by Virtual Screening and Agonists of β2AR (8) or β3AR (9) Designed Using
the Available Crystal Structure Data
Scheme 3. Antagonists of the Adenosine A2A Receptor
Identiﬁed by Virtual Screening or Designed Using the Recent
Crystal Structure Data4299 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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antagonist (Ki = 6 nM) with 20-fold selectivity versus the
adenosineA2Areceptor.Bothofthesestudiesofvirtualscreening
versus the adenosine A2A receptor identified hits that were small
polarmoleculeswithrespectableligandefficiencyvalues(LE).
132
Ivanov et al. docked various known ligands into homology
models of adenosine A2AR based on both bovine rhodopsin
and β2AR-T4L.
133 The model using β2AR-T4L as the template
gave the best results. Problems with the bovine rhodopsin
derived homology model were mainly related to the loop
structure in the region of the binding site. Docking of the ligand
ZM241385 could be further improved by adding crystallogra-
phicallyobservedwatermoleculesorbyusingconstraintsderived
from SDM experiments. Docking of agonists (such as NECA)
were also proposed and indicated that the ribose ring of the
agonist interacted with Ser277 (7.42) and Thr88 (3.36), which
have previously been identified by SDM studies as important for
agonist but not antagonist affinity.
68 An early example of the use
of the A2AR-T4L protein ligand structure being leveraged for
drug design has been reported by Pastorin and co-workers.
134 A
new panel of triazolotriazine derivatives was designed from
docking experiments with the program GOLD using the crystal
structure coordinates and also homology models including the
A3receptor.Theresultsallowedrationalizationofthestructure 
activity relationships within the series as it developed and could
account to some extent for selectivity between A2A and A3.A
representative example is compound 12 (Scheme 3), which is a
potentandselectiveadenosineA2Aantagonist.Akeyobservation
was that the presence of a less bulky amino acid (Val169) in the
ECL2 of the adenosine A3 receptor seemed to have a key
influence over molecules containing larger substituents on the
amino group of the heterocyclic core, modulating potency and
selectivity for the A2A receptor versus the A3 subtype.
7.3.DopamineReceptors.AcomparisonofthedopamineD3
receptor with dopamine D2 indicates that 17 of 18 primary
contact residues are conserved in the dopamine D2 receptor
subtype. This rationalizes the historical difficulty in designing
subtype-selective ligands for the dopamine receptor.
62,135,136
Homology modeling of the dopamine D2 receptor and
docking of the dopamine D3-selective antagonist ligand R22
(13,Scheme4)intothestructure(D3)andthe model(D2)have
recently been performed.
36 The results suggested that while the
amine group of R22 binds to Asp110 (3.32) in the primary
binding pocket as expected, the ligand might adopt an extended
conformation that allows the indole-2-carboxamide to access an
extended binding site formed by ECL1, ECL3, and residues at
thetopofTM1,TM2,andTM7,whicharelargelynonconserved
between the two receptor subtypes.
36 The interactions with this
second binding site were proposed to be the drivers of selectivity
for the dopamine D3 receptor. This bitopic mode of binding has
been previously suggested for the muscarinic M2 receptor partial
agonist McN-A-343
35 and indeed may represent a general
mechanism of action of many ligands that display high selectivity
betweencloselyrelatedreceptorsubtypes(discussedearlier). An
analysis of the homology model published by Ehrlich et al. based
ontheβ2ARstructurerelativetothedopamineD3receptorX-ray
structure is discussed later in the section Discussion and Per-
spectives of this review (Figure 9).
136
7.4. CXCR1/2 Receptors. Allegretti et al. have developed a
model of chemokine CXCR1 bound to (R)-ketoprofen 14
(Scheme5),apotentnoncompetitiveinhibitorofCXCL8-induced
human neutrophil chemotaxis.
137 By use of these data, the binding
site was proposed to be located in the TM bundle with ligands
forming key interactions with Tyr46 (1.39), Lys99 (2.64), and
Glu291(7.35).ThemodelwassupportedfurtherbySDMandalso
ligand photoactivation studies. Compounds were then designed
usingthemodel, leadingeventually toanagentthatwasselectedas
a clinical candidate for prevention of post ischemia reperfusion
injury. The derivative, called repertaxin 15, is an analogue of
ibuprofen and is a rare example of where structure-based design
methodshavebeenreportedtohaveaidedintheidentificationofa
GPCR drug candidate.
7.5. Muscarinic M1 Receptor. The development of selective
M1 muscarinic acetylcholine receptor (mAChR) agonists for
cognitive disorders has long been a goal of the drug discovery
community, but most attempts have resulted in compounds that
display insufficient selectivity. The identification of M1 subtype
selectiveagonists,AC-4216and77-LH-28-117(Scheme6),that
utilized an allosteric binding site on the receptor
138,139 reignited
interest in the field. Interestingly, the agonist activity of AC-42
wasinsensitivetomutationofTyr381(6.51)andAsn382(6.52),
which dramatically reduced the potency of carbachol.
138 Recent
efforts have utilized SDM and homology modeling of the M1
mAChR based on bovine rhodopsin and β2-AR to define the
nature of this allosteric binding site.
140 These studies suggested
thattheselectiveagonistsstillinteractwiththeconservedAsp105
(3.32)toactivatethereceptor butmakefurtherinteractionswith
residues at the extracellular end of TM2 and TM3, areas of the
receptor that are less well-conserved across subtypes;
140 again, it
is this bitopic binding mode that likely confers the selectivity
profile.
Using this information in combination with the crystal struc-
ture of rhodopsin allowed creation of a homology model of the
M1 mAChR in which the important regions of receptor around
theorthostericbindingsiteandthesiteattheextracellularendof
TM domains 2, 3, and 7 were well-deﬁned. This model of the
receptorwasthenusedforvirtualscreeningtoidentifyputatively
Scheme 4. Selective Dopamine D3 Receptor Antagonist, the
Selectivity of Which Can Be Rationalized Using the D3R
Crystal Structure
Scheme 5. Design of a Clinical Candidate for the CXCR1/2
Chemokine Receptor Driven by Homology Modeling and
SDM Data4300 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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selective M1 mAChR agonists; this approach yielded approxi-
mately 1000 hit compounds.
141 Most notable was the benzimi-
dazalone (18) (Scheme 6), which was weakly active at the M1
mAChR (EC50 = 400 nM) but was shown to be inactive at the
M2 M5 mAChR subtypes. Optimization of the N-capping
group and substitutions on the phenyl ring improved metabolic
stability, ultimately leading to compound 19 (Scheme 6) which
displayed increased M1 mAChR potency (EC50 = 8 nM),
maintained subtype selectivity, and had low to moderate clear-
ance in rat in vivo. Compound 19 was subsequently shown to be
active in a rodent model of cognitive impairment and also by
in vivo electrophysiology, suggesting that it wouldbe suitable for
furtherdevelopment.
141Anotherinterestingdevelopmentinthis
ﬁeld has been the identiﬁcation of BQCA 20 (and analogues), a
subtype selective positive allosteric modulator that is thought to
be able to engage with residues at the top of TM7 and in ECL2,
binding concomitantly with acetylcholine to potentiate its ago-
nist activity (Scheme 6).
142
7.6. GPR109 Receptor. Boatman, Richman, and Semple
recently reviewed the area of nicotinic acid receptor GPR109a
and GPR109b research.
108 They discussed the available muta-
genesis and chimera studies that help define the binding site of
nicotinic acid. Arg111 (3.36) in TM3 is considered the key polar
interaction with the carboxylic acid of the ligand, and the pyridyl
ring is suggested to sit in a box of aromatic residues on ECL1,
ECL2, and TM7. Deng et al. have used a homology model to
successfully optimize a series of anthranilic acid amides to derive
potent GPR109a agonists.
143 The model used bovine rhodopsin
(IL9H) as the starting point, and the initial hit molecule 21
(Scheme 7) was proposed to bind to Arg111 (3.36) and Arg251
(6.55), again forming a salt bridge with the carboxylate of the
ligand. Ser178 (ECL2) was proximal to the amide carbonyl of
the hit and might also be involved in H-bonding. SDM studies
wereusedtosupportthebindingproposalandsuggestedthatthe
amideoftheligandinteractedwithIle254(6.58),Phe255(6.59),
and Phe276 (7.35). Thisregion was first probed withcompound
design, and a naphthyl group introduced into the ligand sig-
nificantly improved agonist affinity. Next, targeting several polar
groups at the mouth of the binding pocket with substituents on
the naphthyl led to compound 22 (Scheme 7), which was a
potent full agonist of GPR109a. This analogue also had a good
ADME profile and in vivo efficacy.
7.7. Cannabinoid CB1 Receptors. The cannabinoid recep-
tors are another important class of receptors that have received
much attention in recent years.
144 148 Tuccinardi et al. have
constructed homology models of cannabinoid receptors CB1
and CB2 in the agonist conformation starting from bovine
rhodopsin and using extensive SDM data to refine and improve
confidence in the results.
149 Docking of agonists was carried out,
and selectivity for CB2 over CB1 was rationalized as being
derived from Ser112 (3.31) and Phe197 (5.46) in CB2, which
correspondtoGly195(3.31)andVal282(5.46)inCB1.Docking
of a number of classes of known ligands seemed to support the
hypothesis and to build on earlier models of these receptors.
150
The binding modes and ligand receptor interactions of inverse
agonists taranabant 23 and rimonabant 24 (Scheme 8) with the
CB1 receptor have been studied by Lin et al.
151 Ligand con-
formations were established by X-ray crystallography and NMR
in solution. A homology model derived from bovine rhodopsin
was then constructed, and new and historical SDM data were
used to refine the ligand binding models. The key H-bonding
interaction for taranabant was proposed as Ser383 (7.39), and
the binding site for the two ligands appeared to largely overlap.
However, the key polar interaction for rimonabant (as indicated
from the SDM data) was Lys192 (3.28), so the ligands were
proposed to differ in their key interactions in fine detail.
7.8. Bradykinin B1 Receptor. Kuduk et al. have used a
homology model of the bradykinin B1 receptor to design more
potent analogues of a 2,3-diaminopyridine hit series.
152,153
The homology model was derived from bovine rhodopsin
and had previously been used in modeling of a series of
Scheme 7. Identiﬁcation of a GPR109a Agonist Optimized
Using Homology Modeling of the Receptor
Scheme 6. Identiﬁcation by Virtual Screening and Lead
Optimization of a Selective Muscarinic M1 Receptor Agonist
Scheme 8. Cannabinoid CB1 Receptor Antagonists Whose
Binding Modes Have Been Rationalized by Homology
Modeling and SDM Data4301 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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dihydroquinoxalinones.
154 The model was used to help design
and rationalize the SAR of the 4-pyridylpiperazine analogue 26,
derived from the unsubstituted compound 25 (Scheme 9);
movement of the pyridyl nitrogen atom to the 2- or 3-position
significantly reduced affinity. Mutagenesis of the site also sup-
portedthecredibilityofthemodelforSARgenerationwithinthis
series of potent antagonists.
7.9. 5HT Receptors. Sela and colleagues have outlined the
drug design approach at EPIX Pharmaceuticals and described in
silicoscreeningofover20GPCRs.
155Thefocusonstructure-based
methods led to a good success rate in both screening and lead
optimization for a range of targets. Four clinical candidates were
identified in less than 4 years (PRX-08066, PRX-03140, PRX-
07034, and PRX-00023) targeting the 5-HT receptor family.
156
The philosophy of using rational approaches for hit and lead
optimization throughout the drug discovery process suggests an
advantage in using SBDD over empirical methods.
8. DISCUSSION AND PERSPECTIVES
SBDD using protein ligand crystallography is now the estab-
lishedparadigmforenzymetargets,suchaskinase,proteases,and
phosphodiesterases, and is having a signiﬁcant impact on the
pipelines of pharmaceutical companies. Until very recently
GPCR research has been limited to homology modeling sup-
ported by SDM studies and to empirical SAR used to develop
ligand-based pharmacophores. The new era of protein ligand
X-ray crystallography for GPCR targets is quickly starting to
open up the huge potential of SBDD to medicinal chemists for
GPCR targets. Given the investment within the GPCR drug
discovery community on SDM studies, there is also intriguing
potential to couple X-ray crystallography results with extensive
mutagenesisdataforsomereceptors.Forexample,theadenosine
receptor family has been exhaustively interrogated by SDM for
many years and we are now ina position to rationalizethesedata
withthecrystalstructuresofbothantagonistandagonist ligands.
Thislevelofunderstandingisprobablyunique indrugdiscovery,
as in the enzyme drug discovery community SDM methods are
rarely utilized, being seen as unnecessary where crystal structure
data are available. However, a protein ligand complex does not
give any predictions of binding aﬃnity in its own right, the value
of individual interactions formed being a judgment of the viewer
based on compound SAR and intuition. In our own laboratories
we have developed a method called Biophysical Mapping in
whichastabilizedreceptor(StaR)constructisstudiedbySDMin
a biophysical screen using surface plasmon resonance (SPR).
157
This direct binding approach does not require a radioligand or
other labeling of the compounds being studied. This then allows
panelsofcompoundstobescreenedandthecontributiontotheir
binding of individual residues to be rapidly enumerated. This
method has been coupled withX-raycrystallography datafor the
adenosine A2A receptor and rapidly allowed optimization of a
series of antagonists to yield a preclinical candidate targeted at
the treatment of Parkinson’s disease (unpublished results). The
use of this and other SDM approaches, linked with X-ray data,
promises to revolutionize GPCR research.
The detailed understanding we now have of the β-adrenergic
and adenosine A2A receptors, as well as structures of rhodopsin
and opsin, greatly improves our ability to produce quality
homology models of GPCRs for use in virtual screening and
SBDD. Models created between 2000 and 2008 used bovine
rhodopsin as the starting point for model generation and were
limited by the lack of data on a system with a noncovalently
bound ligand.
158 160 Homology modeling can now be carried
out with much more conﬁd e n c et od e r i v ep r o t e i n  ligand
binding site information for GPCRs of interest, but a careful
Scheme 9. Bradykinin B1 Receptor Antagonist Optimized
Using a Homology Model of the Receptor
Figure 9. (A) Comparison of a dopamine D3 receptor homology model based on the β2AR. (B) Homology model structure (green protein and green
meshcarbonaccessiblesurfacefromGRIDcalculatedusingtheCH3probeat1kcal/molcontour;piperazineligandingreen)andtheX-raystructureof
D3R(grayprotein,X-rayligandeticloprideandcarbonaccessiblesurfaceintransparentsolidrendering).Twooftheresiduesinthehomologymodelthat
restrict the binding site are highlighted by being displayed in green colored stick.4302 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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choice of which template to use as the basis of any new
homology model must be made.
57,161 There is a very large body
of literature on the modeling of GPCRs, their binding sites, and
protein ligand interactions, and the area has been extensively
reviewed.
102,121,129,156,162 Virtual screening applications, leading to
theidentiﬁcationofhitseries,havebeenafocusofinterestinthepast
decade,andwiththeadventofthenewGPCRstructuresevenmore
eﬀort can be expected in this area.
56,67,112,113,117,118,131,163
However,whilehomologymodelsofGPCRshavebeenuseful
to generate hypotheses for SAR and selectivity and with mixed
success for virtual screening, modeling of extracellular loops
remainsacriticalissue.Oftenthemodelwillalsohaveaninduced
ﬁt to the ligand(s) used during its generation. The recent
availability of X-ray structures with noncovalently bound ligands
such as the β1AR and β2AR structures in addition to rhodopsin
structures improves our ability to generate good models, but we
believe additional experimental information from SDM is key to
giving higher conﬁdence binding modes for ligands. This allows
much more conﬁdence inmodels forcompoundSAR and allows
virtualscreeningconstraintstobeappliedtoenablethediscovery
of new ligands (e.g, for our own adenosine A2A project men-
tionedabove).Asanexampleofamodelgeneratedfromthenew
βAR structures,inFigure 9 we comparedahomologymodelof a
ligand bound to the dopamine D3 receptor generated by Ehrlich
et al. from the β2AR structure with the dopamine D3 receptor
X-ray structure.
136 The overall model is very close to the X-ray
solution, as can be seen from the transmembrane backbone
helices (rmsd of 1.4 Å using Maestro from Schr€ odinger).
However, at a detailed level, there are some constrictions to
the modeled binding site from particular residues that aﬀect the
dockingofotherligandssuchastheX-rayligandeticlopride.This
is a general issue when using any homology model in which the
backbone atoms may be slightly shifted and the amino acid
side chain conformations are derived from a library or related
structure with an optional induced ﬁt to a particular ligand.
Indeed, even in experimental structures a diﬀerent ligand can
induce changes within a given binding site. In Figure 9 the
homology model iscompared to theX-raystructure using GRID
carbon accessible surfaces.
50,51 It can be seen that part of the
regionoccupiedbytheX-rayligandeticloprideisoccludedinthe
model (highlighted by displaying in stick are two of the side
chain residues in the homology model causing this). An attempt
to dock eticlopride into the homology model using GLIDE
XP (Schr€ odinger) produced poses where the ligand had to shift
away from the occluded region. This example shows how
challenging it is to produce a general model for ligand docking,
even when very similar to the X-ray structure, and how small
diﬀerences between the model and the X-ray structure can
perturb theresults.Thisexample reinforces the need toregularly
challenge homology models using SDM and compound SAR to
iteratively improve the working model being used and also
highlights the value of actual experimental crystal structures over
modeling.
Watermoleculesplayakeyroleintheligandbinding,eitheras
part of the binding process (interstitial) or most frequently by
providingfree energygains upontheir displacement.Athorough
consideration of waters can be very important to improve dock-
ing and design predictions. Often the limited resolution of
protein X-ray structures means that only some, or none, of the
waters in the binding site are resolved, and even then their
experimental basis (electron density) can be very weak. This is a
problem for most current GPCR structures. A new approach
called WaterMap from Schr€ odinger that uses molecular dy-
namics simulations
164 provides a computational method to
quantify water energies for apo or liganded structures in the
binding site relative to bulk solvent. In Figure 10 the adenosine
A2A receptor binding site (PDB code 3EML) with the
ZM241385 ligand is shown with water positions calculated
(with no ligand present), color-coded to show the most “un-
happy” waters vs bulk solvent waters as red and then yellow
(based on total free energy, summing the entropic and enthalpic
components calculated). There are a large number (∼75%) of
“unhappy” waters deep in the pocket, many unexploited by the
ZM241385 ligand. This might then explain why hits with
relatively high potency and ligand eﬃciency can be identiﬁed
for this target. The GRID maps in the ﬁgure also highlight the
liphophilicandwaterprobehotspots;some“unhappy”watersare
inlipophilichotspots,butpredictionsbasedonlyonthisperform
poorly because the energies do not take into account the whole
network (a better correspondence has been noted in some
enzyme binding sites, where more waters occur on the protein
surface, but false positives and negatives still occur). The various
GRID probes (lipophilic, H-bond acceptor and donor, etc.) also
provide a key indication of what chemical groups would be
complementary to the protein, working well in partnership with
WaterMap in guiding design. WaterMap calculations can also be
done with the ligand present and suggest regions to explore and
Figure 10. Adenosine A2A binding site from the 3EML structure with
the ZM241385 ligand with waters calculated (with no ligand present)
using the WaterMap program from Schr€ odinger shown.
164 These are
colorcodedtoshowthemost“unhappy”vsbulksolventasred(>3.5kcal/
mol), then yellow(2.2 3.5 kcal/mol),with grayintermediate( 1t o2 . 2
kcal), and blue “happy” (<1 kcal/mol). GRID maps highlight the shape
(Csp3 (C3) at 1 kcal/mol in light gray) of the lipophilic hotspots
(aromaticC Hprobe(C1d)i ny e l l o wa t 2.5kcal/mol)andthewater
probe hotspots (in green at  6.6 kcal/mol). Note the large number of
“unhappy” waters deep in the binding site that are not exploited by
ZM241385.4303 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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anyliganddestabilization oftheremainingwaternetwork. These
new computational tools, used to assist in optimization of
homology models and throughout SBDD campaigns, oﬀer great
potential to maximize the utility of the newly available GPCR
X-ray structural information.
Figure 11 describes a cartoon model of our current under-
standing of the antagonist to agonist transition for family A
GPCRs with small molecule natural ligands. Although prelimin-
ary, the recent progress with X-ray structures of systems with
both agonists and antagonists bound, detailed earlier, allows
some proposals to be made on a general mechanism of this
crucial process. The antagonist GPCR conformation is relatively
open and available for the diﬀusion of ligands into the TMD
bindingsite.ThereisalargebodyofevidencethatGPCRligands
bind to a common site on the extracellular face in the center of
the seven helices, and a general feature is the presence of
conserved hydrogen bonding or charged residues to interact
with the natural ligand.
165 For example, in aminergic GPCRs
there is an acidic residue at position 3.32 always present to bind
tothebasicamine intheligands, andinmanyreceptorsthereisa
hydrogen bonding residue at position 6.55; these important
clustersofresidueshaverecentlybeentermed“chemoprints”.
103,162
This region in the orthosteric site is labeled as the H-bonding
subsite in Figure 11. Deeper in the pocket, the TMD site is often
largely hydrophobic or aromatic in character, and this region has
previously been recognized and called the “conserved” site.
166 In
Figure 11 this area is labeled as the lipophilic subsite. The two
regions (H-bonding and lipophilic) of the orthosteric site of the
CB1 receptor have previously been called aromatic and polar
microdomains.
144 At the entrance to the pocket, adjacent to
ECL2 we propose that there will generally be an allosteric binding
site where negative allosteric modulators or the extended part of
bitopic ligands bind but small molecule orthosteric ligands do not
interact. This has been previously called the “variable” region, as it
was recognized as a potential site for larger ligands to derive
selectivity for a speciﬁc receptor subtype.
166 Also encompassed
bythisproposedallostericsiteisaregionrecentlycalledthe“minor
groove” suggested as a selectivity pocket and also to have a role in
signalingandreceptoractivation,nexttoTM2,TM7,andECL2.
167
In family A peptide receptors the allosteric site in Figure 11 would
actually be part of the “address”region for the peptide ligand while
the area labeled the orthosteric site in Figure 11 would be the
“message” region (discussed earlier).
73 After initial binding of the
naturalagonisttothisformofthereceptor,conformationalchanges
probably driven by formation of new polar interactions with the
ligand and a closing-in around the binding site will occur to form
the receptor agonist complex. As described earlier, although the
changes within the binding site on complexation of agonists are
quite subtle, there seem to be key polar interactions formed to
agonists that are not involved in antagonist binding. Indeed,
a n t a g o n i s t sa l s ot e n dt ob el a r g e r ,h o l d i n go p e nt h er e c e p t o rt o
prevent the conformational changes involved in agonist signaling.
In Figure 11 we therefore propose the formation of a “signaling
subsite”ontransitiontothereceptor agonistcomplex,whichmay
itself be a precursor to the proposed rotation of the toggle switch
and further changes to the so-called microswitches upon G protein
binding on the intracellular surface.
45 T h ec h a n g e si nt h ea l l o s t e r i c
site (now the site of engagement of PAMs) are uncertain, but this
site must have an overall diﬀerent shape such that PAMs stabilize
the agonist conformation of the receptor. Rather than considering
the conformation of the receptor binding to NAMs or PAMs as
discrete forms in solution, our suggestion is that these modulators
bind to the same conformations as antagonists or agonists,
respectively,butare noncompetitivewithrespecttotheorthosteric
binding site, i.e., that there is a simple two-state model operating.
This is consistent with our observations upon conformational
thermostabilization of multiple receptors to form StaRs, where
either the agonist or antagonist state appears to be trapped by a
wide range of ligands, with no evidence for trapping of any other
conformations during these studies. Finally, agonists appear to
engage in the H-bonding subsite in a manner similar to that of
antagonists, and this suggests that agonists can bind to both
conformations of the receptor and act to pull the equilibrium over
totheactivestate.Antagonistsandinverseagonists,however,inthe
Figure 11. Simpliﬁed description of family A GPCR binding sites in the antagonist and agonist conformational states. Antagonists bind to both
H-bondingandlipophilicsubsitesinamoreopenformoftheorthostericpocketofthereceptor.NAMsareproposedtooccupyanallostericpocketatthe
entrancetothereceptoradjacenttoECL2.Agoniststriggerachangeinreceptorconformationonbindingtotheantagoniststateinwhichthevolumeof
thebindingsitedecreasesandnewpolarinteractionsareformeddeepinsidethepocketclosetothetoggleswitchW6.48.PAMsareproposedtostabilize
the agonist state by binding to the allosteric pocket in an alternative conformation.4304 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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model proposed here, will only be capable of binding to the
antagoniststate,astheytendtobelargerthanagonistsandsterically
blocked from binding to the agonist state.
Theanalysisabovesuggeststhatsubtypeselectivitymightbest
be derived by accessing an allosteric site of either antagonist or
agonistreceptorconformationsandthattargetingtheorthosteric
site may not be proﬁtable. However, if we compare this situation
to the kinase enzyme family, we can draw some parallels. In
kinases close to the hinge that binds the adenine of ATP, many
kinases are similar and within kinase subtypes this part of the
active site is very similar indeed. However, it has been shown
many times that small diﬀerences in this region between close
family members can be used to derive selectivity without neces-
sarily requiring large extended ligands that access more variable
regions outside this region of the binding site.
168 Figure 12 shows
thebindingsitesofβ1AR andβ2ARoverlaid.
58,60Veryclosetothe
ligandstherearetworesiduechangesbetweenβ1andβ2:Phe325/
Tyr308 (7.35) and Val172/Thr164 (4.56). The Tyr308 (7.35) in
β2AR forms a hydrogen bond to Asn293 (6.55), which is missing
in β1AR where the Phe325 (7.35) cannot make this interaction.
This has the eﬀect of changing the positions of the aromatic rings
ofPhe325(7.35)andTyr308(7.35)relativetoeachotherandalso
of the nearby Asn310/293 (6.55) between the two systems. In
β1AR the Asn310 (6.55) is capable of forming a weak hydrogen
bond to the ligand cyanopindolol, while in β2AR this residue is
not available to bind to the ligand in the same way (Figure 12).
Overall, the surface of the ligand-binding pocket made by these
residue pairs has a subtly diﬀerent shape and polarity, which
might be expected to allow for the design of selective ligands.
In our own research on the structure based optimization of a
series of adenosine A2A antagonists, selectivity was achieved
overotheradenosinereceptorsubtypes“inside” theorthosteric
site, taking advantage of similar small diﬀerences between the
subtypes and without accessing the allosteric region at the
entrance to the binding site (unpublished results).
With the advent of SBDD for GPCRs, fragment based drug
discovery (FBDD) becomes an attractive opportunity for the
GPCR drug discovery community.
169 171 Fragments are simply
low molecular weight organic molecules, usually deﬁned as
100 250 Da in size, and as such are much smaller than hits
typically identiﬁed by other methods such as HTS. As we have
seen,theGPCRbindingsitesforfamilyAreceptorsarelargeand
generallyhydrophobicbutcontainkeyH-bondingpolarresidues
for both binding and signaling. GPCR systems should be highly
suitable for FBDD approaches, and fragments with high ligand
eﬃciency (LE) may be detectable.
132 Often, however, fragments
bind promiscuously and might bind to multiple receptors,
potentially making triaging of hits (often done by evaluating
selectivity) more challenging. Albert et al. have described their
experiences of FBDD and gave high concentration screening
(HCS) results for some GPCR targets, indicating that respect-
able hit rates can be achieved.
172 Unfortunately, false positives
could not be readily identiﬁed, as there were no orthogonal
biophysical assays in which to evaluate the hits and no access to
X-ray cocomplexes available at the time. In one example, the
melanocortin4receptor,60conﬁrmedhitswereidentiﬁedfroma
library of 660 fragments screened at 1 mM. Near-neighbor
screening of commercial analogues produced hits with more
conventional potency (10 50 μM) but at the expense of a
signiﬁcant reduction in LE, suggesting that the larger and more
active analogues were not binding optimally in the receptor. In
another more recent example, a ligand-based NMR method has
been successfully applied to GPR40 to identify hits, and this
methodhasthepotentialforuseinFBDD.
173Intheauthors’own
research,wehaveusedStaRstoseveralGPCRsinbothfamiliesA
and B as reagents for fragment based screening using high-
concentrationscreens,surfaceplasmonresonance(Biacore),and
target-immobilizedNMR(TINSNMR)basedscreening.
174SPR
screening of an A2A-StaR and TINS NMR screening of a β1AR
StaR both identiﬁed hits that could be validated by showing
activity in orthogonal assays. Both of these biophysical methods
depend on immobilizing the stabilized receptor on a surface and
then ﬂowing a solution of fragments in buﬀer through the
instrument. Fragment binding is then detected by either an
increase in mass bound to the chip (response units) or a change
in the NMR signal of the fragment. For example, simple
xanthines were readily identiﬁed as binders to the A2A-StaR
and a medium resolution crystal structure for caﬀeine was
subsequently solved in the A2A-StaR X-ray system.
66 These
ﬁndings using StaR proteins for FBDD methodologies are
promising, suggesting that leveraging of the range of biophysical
tools currently available for soluble proteins can now be con-
templated for GPCR targets.
Inconclusion,theﬁeldofGPCRdrugdiscoveryissettohavea
new lease of life, invigorated by a quantum leap of progress in
structuralbiologyoverthepast3years.TheneweraofSBDDfor
GPCRs should now allow even some of the most challenging
targetstoyieldtotheeﬀortsofmedicinalchemists.Thisverywell
establisheddrug family can expect to see many more ﬁrst in class
agents and better molecules with improved physicochemical
properties and selectivity proﬁles, derived from the careful,
rational optimization of hits using structure based and fragment
based methods. In particular, a disciplined emphasis on maintain-
ing high ligand eﬃciency and ligand lipophilicity eﬃciency should
allow thenextgenerationofresearchonthistargetfamilytoproﬁt
fromimprovedclinicalsuccessratesandleadtosafeandeﬃcacious
medicines over the next decade.
5,132 These are exciting times.
Figure 12. Potential for selectivity in β-adrenergic receptors: super-
imposition of crystal structures of cyanopindolol in β1AR (yellow) and
carazolol in β2AR (blue) adrenoceptors. The surface of the pocket in
β1ARslightlydiﬀersfromtheshapeofthepocketinβ2ARbecauseofthe
lack of the phenol hydroxyl group in Phe325 (7.35) (β1) vs Tyr308
(7.35) (β2). This single atom change also aﬀects the H-bonding of the
adjacent Asn residue (6.55) in the binding site.4305 dx.doi.org/10.1021/jm200371q |J. Med. Chem. 2011, 54, 4283–4311
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